PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Inclusion Criteria: * Confirmed diagnosis of relapsed/refractory CLL/SLL who require treatment and have failed at least one prior therapy. * Patients must have available results of interphase cytogenetics CLL fluorescent in situ hybridization (FISH) panel; the cytogenetic analysis must be done prior to starting therapy but after any recent therapy * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Life expectancy greater than 2 months * Bilirubin =\< 1.5 X the institutional upper limit of normal unless due to Gilbert's disease or disease related to Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 2.5 X the institutional upper limit of normal unless disease related * Creatinine =\< 1.5 X the institutional upper limit of normal unless disease related * Absolute neutrophil count (ANC) \>= 0.75 X 10\^9/L * Platelet count \>= 30 X 10\^9/L * Agree to use contraception during the study and for 30 days after the last dose of study drug if sexually active and able to bear children * Ability to understand and the willingness to sign a written informed consent document * Patients with uncontrolled or active infection requiring antibiotic therapy; patients with controlled infections who are receiving extended antibiotics or prophylactic therapy are not excluded Exclusion Criteria: * Patients who have had chemotherapy, radiotherapy or immunotherapy within 4 weeks prior to the first dose of study drug (corticosteroids for disease-related symptom…